Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
positive save search
AGBA Group is Positioned For Hong Kong's Rebounding Macro Environment with Business Refinements and Growth Strategies
Published: 2024-02-27 (Crawled : 14:00) - globenewswire.com
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
|
| O: 5.49%
H: 0.0%
C: -11.46%
business group growth
Benitec Biopharma Provides Positive Updates on the BB-301 Pilot Dosing Study in Large Animals
Published: 2021-09-08 (Crawled : 12:00) - ir.benitec.com
BNTC | $6.89 1.03% 1.02% 250K
|
Health Technology
|
| O: -1.53%
H: 2.34%
C: -1.82%
bb-301 biopharma animals positive
Benitec Biopharma Provides Positive Regulatory Updates for the BB-301 Development Program; BB-301 Phase 1b/2a Clinical Trial to Begin in 2022
Published: 2021-09-08 (Crawled : 12:00) - ir.benitec.com
BNTC | $6.89 1.03% 1.02% 250K
|
Health Technology
|
| O: -1.53%
H: 2.34%
C: -1.82%
bb-301 biopharma phase 1 positive trial phase 1b phase 2b
Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study
Published: 2024-04-18 (Crawled : 12:00) - biospace.com/
BNTC | $6.89 1.03% 1.02% 250K
|
Health Technology
|
| O: 5.41%
H: 41.06%
C: 29.66%
bb-301 first positive biopharma for trial opmd study
Portage Biotech Highlights First Patient Dosed in PRECIOUS-01 Study of PORT-3 for the Treatment of NY-ESO-1 Positive Solid Tumors
Published: 2021-04-08 (Crawled : 15:00) - biospace.com/
PRTG | $0.28 16.67% 14.29% 280K
|
Mining, Quarrying, and Oil and ...
|
| O: 0.0%
H: 2.26%
C: -3.87%
treatment solid tumors positive biotech iot
DEEP GREEN Completes Asset Sale of Georgia Subsidiary and Strengthens Company Cash Position
Published: 2024-03-25 (Crawled : 12:30) - globenewswire.com
DGWR | $0.1199 -98.05% 190
|
Manufacturing
|
| O: 38.16%
H: 0.0%
C: -25.81%
company
Bio-Path Holdings Announces Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia
Published: 2023-08-01 (Crawled : 11:00) - globenewswire.com
BPTH | News 0 d | $4.17 -0.71% -0.96% 2.1M
|
Health Technology
|
| O: -2.28%
H: 0.47%
C: -8.4%
positive leukemia trial results phase 2
Swvl Announces Portfolio Optimization Program to Turn Cash Flow Positive in 2023
Published: 2022-05-31 (Crawled : 08:00) - prnewswire.com
SWVL | $10.4 9.71% 8.85% 130K
|
n/a
|
| O: 0.0%
H: 10.84%
C: 5.32%
program flow positive
Eledon Announces Positive Topline Results from Phase 2a Trial of Tegoprubart Demonstrating Safety, Target Engagement, and Biomarker Response in Patients Living with Amyotrophic Lateral Sclerosis
Published: 2022-05-31 (Crawled : 11:00) - biospace.com/
ELDN | $1.85 -7.03% -7.57% 420K
|
Manufacturing
|
| O: 4.2%
H: 6.18%
C: -14.25%
topline trial response positive results living sclerosis biomarkers phase 2b
Tiziana Announces Positive Qualitative Six-Month PET Scan Results With Intranasal Foralumab Treating Multiple Sclerosis Patients Diagnosed With Non-Active Secondary Progressive MS (na-SPMS)
Published: 2023-10-13 (Crawled : 11:00) - globenewswire.com
TLSA | News | $0.6698 4.66% 4.45% 600K
|
Health Technology
|
| O: 7.15%
H: 8.49%
C: 0.92%
foralumab positive sclerosis results scan
Tiziana Life Sciences Announces Positive Six-Month Clinical Results in Multiple Sclerosis Patients Treated with Intranasal Foralumab
Published: 2023-10-16 (Crawled : 11:00) - globenewswire.com
TLSA | News | $0.6698 4.66% 4.45% 600K
|
Health Technology
|
| O: 8.75%
H: 8.05%
C: -2.3%
life foralumab positive sclerosis sciences results
Veru Reports Positive Phase 2 Clinical Trial Results for Enobosarm, Selective Androgen Receptor Targeting Agent, for Endocrine Resistant Metastatic Breast Cancer
Published: 2020-12-14 (Crawled : 13:01) - globenewswire.com
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 55.31%
H: 9.73%
C: -1.77%
results breast cancer cancer positive endocrine trial trial results phase 2 metastatic breast cancer
Veru Announces Nature Medicine Publication Demonstrating that Enobosarm, an Androgen Receptor Targeted Agent, Inhibits Hormone Receptor Positive Metastatic Breast Cancer that has Become Resistant to Estrogen Receptor Targeted Endocrine and CDK4/6 Inhibitor Therapies
Published: 2021-01-19 (Crawled : 14:01) - globenewswire.com
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 4.43%
H: 1.19%
C: -4.4%
positive endocrine cancer breast cancer hormone therapy metastatic breast cancer
Veru Reports Positive Phase 2 Clinical Results of VERU-111 in Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome
Published: 2021-02-08 (Crawled : 13:26) - globenewswire.com
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 17.94%
H: 22.18%
C: 8.33%
covid positive results respiratory phase 2 risk syndros
Veru Announces Positive Updated Data from Phase 1b/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer at the 2021 ESMO Congress
Published: 2021-09-20 (Crawled : 13:15) - biospace.com/
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: -4.25%
H: 3.62%
C: -1.17%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.14%
H: 1.4%
C: 0.04%
prostate cancer phase 1 positive cancer phase 1b sabizabulin phase 2b
Veru Announces the Presentation of Positive Phase 2 Clinical Data of Enobosarm in AR+ER+HER2- Metastatic Breast Cancer Patients that Have Progressed on Estrogen Blocking Agents and CDK 4/6 Inhibitor at the ESMO Breast Cancer Congress 2021
Published: 2021-05-05 (Crawled : 13:00) - globenewswire.com
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 20.23%
H: 6.88%
C: -15.97%
presentation phase 2 positive cancer breast cancer her2+ her2- her2 metastatic breast cancer
Veru Announces Positive Phase 2 Clinical Data: Efficacy of Enobosarm Therapy Correlates with Androgen Receptor Levels in AR+ER+HER2- Metastatic Breast Cancer Presented at the 2021 ASCO Annual Meeting
Published: 2021-06-07 (Crawled : 13:00) - globenewswire.com
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 0.92%
H: 5.56%
C: 1.82%
phase 2 positive therapy cancer breast cancer her2+ her2- her2 metastatic breast cancer
Veru, Immunome Tout Positive Data for COVID-19 Therapeutics
Published: 2022-07-06 (Crawled : 17:00) - biospace.com/
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 0.26%
H: 20.43%
C: 12.73%
IMNM | $15.5 -9.78% -10.84% 2.1M
|
Health Technology
|
| O: 2.63%
H: 12.54%
C: 9.69%
covid-19 therapeutics positive
FDA Has Granted Veru a Pre-Emergency Use Authorization (EUA) Meeting Date for Positive Sabizabulin Phase 3 COVID-19 Study
Published: 2022-05-02 (Crawled : 13:20) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.92%
H: 0.0%
C: 0.0%
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 8.28%
H: 2.44%
C: -19.07%
covid-19 fda sabizabulin granted authorization positive phase 3 emergency use authorization
FDA States that Veru Should Submit Request for Emergency Use Authorization (EUA) Based on Positive Efficacy and Safety Data from the Phase 3 Clinical Study of Sabizabulin in Hospitalized COVID-19 Patients
Published: 2022-05-11 (Crawled : 11:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -3.03%
H: 0.0%
C: 0.0%
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 20.75%
H: 0.0%
C: 0.0%
covid-19 fda sabizabulin authorization positive phase 3 emergency use authorization
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.